331 related articles for article (PubMed ID: 24304452)
1. Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection.
Casado JL; Quereda C; Moreno A; Pérez-Elías MJ; Martí-Belda P; Moreno S
J Viral Hepat; 2013 Dec; 20(12):829-37. PubMed ID: 24304452
[TBL] [Abstract][Full Text] [Related]
2. Course of liver fibrosis in HIV-hepatitis C virus-coinfected patients depending on the response to hepatitis C therapy.
Cartón JA; Collazos J; de la Fuente B; Asensi V
AIDS Res Hum Retroviruses; 2013 Feb; 29(2):215-22. PubMed ID: 22734850
[TBL] [Abstract][Full Text] [Related]
3. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy.
Labarga P; Fernandez-Montero JV; Barreiro P; Pinilla J; Vispo E; de Mendoza C; Plaza Z; Soriano V
J Viral Hepat; 2014 Jul; 21(7):475-9. PubMed ID: 24750394
[TBL] [Abstract][Full Text] [Related]
4. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.
ANRS CO13 HEPAVIH Cohort
AIDS; 2015 Sep; 29(14):1821-30. PubMed ID: 26372388
[TBL] [Abstract][Full Text] [Related]
5. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
Berenguer J; Alvarez-Pellicer J; Martín PM; López-Aldeguer J; Von-Wichmann MA; Quereda C; Mallolas J; Sanz J; Tural C; Bellón JM; González-García J;
Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364
[TBL] [Abstract][Full Text] [Related]
6. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
Sanmartín R; Tor J; Sanvisens A; López JJ; Jou A; Muga R; Ojanguren I; Barluenga E; Videla S; Planas R; Clotet B; Tural C
HIV Med; 2014 Apr; 15(4):203-12. PubMed ID: 24245909
[TBL] [Abstract][Full Text] [Related]
7. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.
Poynard T; Moussalli J; Munteanu M; Thabut D; Lebray P; Rudler M; Ngo Y; Thibault V; Mkada H; Charlotte F; Bismut FI; Deckmyn O; Benhamou Y; Valantin MA; Ratziu V; Katlama C;
J Hepatol; 2013 Oct; 59(4):675-83. PubMed ID: 23712051
[TBL] [Abstract][Full Text] [Related]
8. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients.
Labarga P; Fernandez-Montero JV; de Mendoza C; Barreiro P; Pinilla J; Soriano V
Antivir Ther; 2015; 20(3):329-34. PubMed ID: 25372299
[TBL] [Abstract][Full Text] [Related]
9. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
10. Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.
Rivero-Juarez A; Neukam K; Labarga P; Camacho A; Macias J; Barreiro P; Torre-Cisneros J; Pineda JA; Soriano V; Rivero A
J Infect; 2014 Apr; 68(4):372-7. PubMed ID: 24269677
[TBL] [Abstract][Full Text] [Related]
11. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
Bani-Sadr F; Lapidus N; Bedossa P; De Boever CM; Perronne C; Halfon P; Pol S; Carrat F; Cacoub P; ;
Clin Infect Dis; 2008 Mar; 46(5):768-74. PubMed ID: 18248298
[TBL] [Abstract][Full Text] [Related]
12. Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies.
Labarga P; Fernández-Montero JV; López M; Barreiro P; de Mendoza C; Sierra-Enguita R; Treviño A; Soriano V
Antivir Ther; 2014; 19(8):799-803. PubMed ID: 24964405
[TBL] [Abstract][Full Text] [Related]
13. Re-treatment of chronic HCV infection in HIV co-infected patients and predictors of sustained viral response.
Krastinova E; Bani-Sadr F; Fromentin D; Goujard C; Hessamfar M; Yazdanpanah Y; Pol S; Cacoub P; Perronne C; Carrat F
J Infect; 2014 May; 68(5):462-6. PubMed ID: 24378283
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
Roche B; Sebagh M; Canfora ML; Antonini T; Roque-Afonso AM; Delvart V; Saliba F; Duclos-Vallee JC; Castaing D; Samuel D
Liver Transpl; 2008 Dec; 14(12):1766-77. PubMed ID: 19025933
[TBL] [Abstract][Full Text] [Related]
15. Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis.
Berenguer J; Zamora FX; Carrero A; Von Wichmann MA; Crespo M; López-Aldeguer J; Aldámiz-Echevarría T; Montes M; Quereda C; Téllez MJ; Galindo MJ; Sanz J; Santos I; Guardiola JM; Esteban H; Bellón JM; González-García J;
J Acquir Immune Defic Syndr; 2014 Jul; 66(3):280-7. PubMed ID: 25157646
[TBL] [Abstract][Full Text] [Related]
16. Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.
Halfon P; Carrat F; Bédossa P; Lambert J; Pénaranda G; Perronne C; Pol S; Cacoub P
Antivir Ther; 2009; 14(2):211-9. PubMed ID: 19430096
[TBL] [Abstract][Full Text] [Related]
17. Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: influence of a sustained HCV response.
Bani-Sadr F; Krastinova E; Fromentin D; Piroth L; Rosenthal E; Quertainmont Y; Perronne C; Cacoub P; Pol S; Carrat F;
J Viral Hepat; 2012 Jun; 19(6):431-5. PubMed ID: 22571905
[TBL] [Abstract][Full Text] [Related]
18. Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.
Hasson H; Messina E; Merli M; Della Torre L; Morsica G; Bagaglio S; Lazzarin A; Uberti-Foppa C
Int J Infect Dis; 2014 Dec; 29():100-2. PubMed ID: 25449243
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
Loko MA; Bani-Sadr F; Valantin MA; Lascoux-Combe C; Fontaine H; Bonnard P; Gervais A; Bouchaud O; Garipuy D; Quertainmont Y; Vittecoq D; Tehrani MS; Winnock M; Dabis F; Salmon D;
Antivir Ther; 2012; 17(7):1335-43. PubMed ID: 23052829
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response.
D'Ambrosio R; Aghemo A; Fraquelli M; Rumi MG; Donato MF; Paradis V; Bedossa P; Colombo M
J Hepatol; 2013 Aug; 59(2):251-6. PubMed ID: 23528378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]